| BIOMARIN PHAR. DL-,001 | 65.07 / 0.00% |
| Date/Time | 10/27 / 08:04 |
| Chg. / Chg.(%) | 0.00 / 0.00% |
| Bid | 65.03 / 100 |
| Ask | 65.32 / 100 |
| Open | 65.07 |
| Previous Close | 65.07 |
| High | 65.07 |
| Low | 65.07 |
| Volume [EUR] | 0.00 |
| Volume [Units] | 0 |
| Price fixings | 1 |
| ISIN | US09061G1013 |
| Security | BM8 |
| Exchange | München |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| Frankfurt | 65.0300 |  |
0 |
| Berlin | 65.01 | |
0 |
| München | 65.07 | |
0 |
| Lang & Schwa.. | 65.02 | |
|
| Stuttgart | 65.040 | |
|
| gettex | 65.060 | |
|
| NASDAQ | 76.8800 | |
1,097,181 |
| IEX | 76.90 | |
103,398 |
| Cboe US | 76.88 | |
26,453 |
| TradeGate | 65.110 | 762 | |
| Mexico | 1,608.00 |  |
70 |
| Düsseldorf | 64.83 | 0 | |
| London Inter.. | 79.40 | 47 | |
| Vienna Globa.. | 65.35 | |
0 |
News
- BioMarin sinks 32% as FDA delays its hemophilia treatment
08/19/2020 / 16:23 - TeleTrader - Nasdaq turns red as pharma stocks fall
04/28/2020 / 16:48 - TeleTrader - BioMarin Enrolls First Participant in Phase 3 Trial of Vosoritide for Treatment of Children with Achondroplasia
12/12/2016 / 14:29 - GlobeNewswire - NICE Recommends BioMarin's Vimizim® (elosulfase alfa) for the Treatment of Morquio A Syndrome in England
11/23/2015 / 16:59 - GlobeNewswire
Real-time